Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia

American Journal of Geriatric Psychiatry

Volumn 20, Issue 9, 2012, Pages 789-797

  Herrmann, Nathan ^a,d   Black, Sandra E ^a,b,d   Chow, Tiffany ^a,b   Cappell, Jaclyn ^d   Tang Wai, David F ^a,b,c   Lanctôt, Krista L ^a,d  

^a BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

^b ROTMAN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Citalopram; frontotemporal dementia; serotonin

Indexed keywords

CITALOPRAM; PROLACTIN; SEROTONIN;

AGED; AGGRESSION; AGITATION; ANXIETY; ANXIETY DISORDER; APATHY; APPETITE; APPETITE DISORDER; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; COGNITIVE DEFECT; CONCENTRATION LOSS; DELUSION; DEPRESSION; DISEASE SEVERITY; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; EUPHORIA; FALLING; FATIGUE; FEMALE; FRONTOTEMPORAL DEMENTIA; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HAPPINESS; HUMAN; IRRITABILITY; LOOSE FECES; MALE; MENTAL DISEASE; MENTAL INSTABILITY; MOTOR DYSFUNCTION; NAUSEA; NEUROENDOCRINE SYSTEM; NEUROPSYCHIATRY; OPEN STUDY; OUTPATIENT; PATIENT REFERRAL; SEROTONINERGIC SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SWEATING; SYNCOPE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84865744207     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e31823033f3     Document Type: Article

References (42)

1. Weder ND, Aziz R, Wilkins K, Tampi RR: Frontotemporal dementias: a review. Ann Gen Psychiatry 2007; 6:15
2. Kertesz A: Frontotemporal dementia: a topical review. Cogn Behav Neurol 2008; 21(3):127-133
3. Mourik JC, Rosso SM, Niermeijer MF, Duivenvoorden HJ, Van Swieten JC, Tibben A: Frontotemporal dementia: behavioral symptoms and caregiver distress. Dement Geriatr Cogn Disord 2004; 18(3-4):299-306
4. Fernandez Martinez M, Castro Flores J, Perez de las Heras S, Mandaluniz Lekumberri A, Gordejuela Menocal M, Zarranz Imirizaldu JJ: Prevalence of neuropsychiatric symptoms in elderly patients with dementia in Mungialde County (Basque Country, Spain). Dement Geriatr Cogn Disord 2008; 25(2):103-108
5. Passant U, Elfgren C, Englund E, Gustafson L: Psychiatric symptoms and their psychosocial consequences in frontotemporal dementia. Alzheimer Dis Assoc Disord 2005; 19(suppl 1):S15-S18
6. Mendez MF, Licht EA, Shapira JS: Changes in dietary or eating behavior in frontotemporal dementia versus Alzheimer's disease. Am J Alzheimers Dis Other Demen 2008; 23(3): 280-285
7. Rosso SM, Roks G, Stevens M, et al: Complex compulsive behaviour in the temporal variant of frontotemporal dementia. J Neurol 2001; 248(11):965-970
8. Tartaglia MC, Kertesz A, Ang LC: Delusions and hallucinations in frontotemporal dementia: a clinicopathologic case report. Cogn Behav Neurol 2008; 21(2):107-110
9. Perry RJ, Miller BL: Behavior and treatment in frontotemporal dementia. Neurology 2001; 56(11 suppl 4):S46-S51
10. Huey ED, Putnam KT, Grafman J: A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006; 66(1):17-22
11. Yang Y, Schmitt HP: Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol 2001; 101(3): 256-270
12. Francis PT, Holmes C, Webster MT, Stratmann GC, Procter AW, Bowen DM: Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy. Dementia 1993; 4(3-4):172-177
13. Procter AW, Qurne M, Francis PT: Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999; 10(suppl 1):80-84
14. Lanct̂ot KL, Herrmann N, Ganjavi H, et al: Serotonin-1A receptors in frontotemporal dementia compared with controls. Psychiatry Res 2007; 156(3):247-250
15. Lanct̂ot K, Hussey D, Herrmann N: Comparisons of serotonin 5-HT1A receptor binding potential in Alzheimer's disease (AD) versus controls using [11C]WAY-100635 and PET [abstract]. Ann Neurol 2003; 54(S7)
16. Lanct̂ot KL, Herrmann N, Mazzotta P, Khan LR, Ingber N: GAB Aergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry 2004; 49(7):439-453
17. Lanct̂ot KL, Herrmann N, Mazzotta P: Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2001; 13(1):5-21
18. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ: Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004; 172(4):400-408
19. Lebert F, Stekke W, Hasenbroekx C, Pasquier F: Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004; 17(4):355-359
20. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A: Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 2003; 49(1):13-19
21. Swartz JR, Miller BL, Lesser IM, Darby AL: Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58(5):212-216
22. Pollock BG, Mulsant BH, Rosen J, et al: Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159(3):460-465
23. Neary D, Snowden JS, Gustafson L, et al: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51(6):1546-1554
24. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44(12):2308-2314
25. Hachinski VC, Iliff LD, Zilhka E, et al: Cerebral blood flow in dementia. Arch Neurol 1975; 32(9):632-637
26. Risch SC, Kalin NH, Murphy DL: Pharmacological challenge strategies: implications for neurochemical mechanisms in affective disorders and treatment approaches. J Clin Psychopharmacol 1981; 1(4):238-243
27. Mattos P, Franco VA, Noel F, Segenreich D, Goncalves JC: Usefulness of serotoninergic challenge with oral citalopram. Rev Bras Psiquiatr 2006; 28(3):203-205
28. Henning J, Netter P: Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests. Int J Neuropsychopharmacol 2002; 5(1):67-71
29. Park SBG, Cowen PJ: Effect of pindolol on the prolactin response to d-fenfluramine. Psychopharmacology 1995; 118: 471-474
30. Palazidou E, Stephenson J, Butler J, Coskeran P, Chambers S, McGregor AM: Evidence for 5-hydroxytryptamine1A receptor involvement in the control of prolactin secretion in man. Psychopharmacology (Berl) 1995; 119(3):311-314
31. Seifritz E, Baumann P, Muller MJ, et al: Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebocontrolled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996; 14(4):253-263
32. Kapitany T, Schindl M, Schindler SD, et al: The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 1999; 88(2):75-88
33. Klein N, Sacher J, Geiss-Granadia T, et al: In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) 2006; 188(3):263-272
34. Kertesz A, Davidson W, Fox H: Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci 1997; 24(1):29-36
35. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA: Cornell Scale for Depression in Dementia. Biol Psychiatry 1988; 23(3):271-284
36. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3):189-198
37. Reisberg B: Functional assessment staging (FAST). Psychopharmacol Bull 1988; 24(4):653-659
38. Gelinas I, Gauthier L, McIntyre M, Gauthier S: Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999; 53(5):471-481
39. Lebert F, Pasquier F, Petit H: Trazodone in the treatment of behavior in frontotemporal dementia. Hum Psychopharmacol Clin Exp 1999; 14:279-281
40. Anneser JM, Jox RJ, Borasio GD: Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler 2007; 8(3):189-190
41. Lanct̂ot KL, Herrmann N, van Reekum R, Eryavec G, Naranjo CA: Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. Int J Geriatr Psychiatry 2002; 17(6):531-541
42. Bowen DM, Procter AW, Mann DM, et al: Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. Psychopharmacology (Berl) 2008; 196(4):603-610